Suzhou-headquartered biotechnology firm Tot Biopharm, which focuses on high-end anti-tumour drugs, has raised $102 million in a Series B funding round co-led by existing investor Chengwei Capital, asset manager 99Fund, and China Universal (Cayman) GP Ltd.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
